Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 1011-1016

  Aoyama, Mineyoshi ^a   Kataoka, Hiromi ^a   Kubota, Eiji ^a   Tada, Toyohiro ^b   Asai, Kiyofumi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Drug resistance; Embryonic stem cell expressed Ras; Neuroblastoma; Phosphatidylinositol 3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; VINBLASTINE;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77956548624     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000752     Document Type: Article

References (24)

1. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477, 1993. (Pubitemid 23228250)
2. Pritchard J and Hickman JA: Why does stage 4s neuroblastoma regress spontaneously? Lancet 344: 869-870, 1994.
3. Yamamoto K, Hanada R, Kikuchi A, et al: Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 16: 1265-1269, 1998.
4. Brodeur GM: Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 31: 505-510, 1995.
5. Brodeur GM and Nakagawara A: Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 14: 111-116, 1992.
6. Ohira M, Morohashi A, Inuzuka H, et al: Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 22: 5525-5536, 2003.
7. Brodeur GM, Azar C, Brother M, et al: Effect of genetic factors on prognosis and treatment. Cancer 70: 1685-1694, 1992.
8. Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124, 1984. (Pubitemid 14106392)
9. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116, 1985.
10. Nakagawara A, Arima M, Azar CG, Scavarda NJ and Brodeur GM: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52: 1364-1368, 1992.
11. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB and Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328: 847-854, 1993.
12. Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D and Beck D: CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 54: 4238-4242, 1994.
13. Berwanger B, Hartmann O, Bergmann E, et al: Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2: 377-386, 2002.
14. Ehrhardt A, Ehrhardt GR, Guo X and Schrader JW: Ras and relatives - job sharing and networking keep an old family together. Exp Hematol 30: 1089-1106, 2002.
15. Tanaka T, Slamon DJ, Shimada H, et al: A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases. Cancer 68: 1296-1302, 1991.
16. Tanaka T, Sugimoto T and Sawada T: Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening. Cancer 83: 1626-1633, 1998.
17. Matsunaga T, Takahashi H, Ohnuma N, et al: Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. Cancer Res 51: 3148-3152, 1991.
18. Nakada K, Fujioka T, Kitagawa H, Takakuwa T and Yamate N: Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis. Jpn J Clin Oncol 23: 149-155, 1993.
19. Kitanaka C, Kato K, Ijiri R, et al: Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J Natl Cancer Inst 94: 358-368, 2002.
20. Takahashi K, Mitsui K and Yamanaka S: Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature 423: 541-545, 2003. (Pubitemid 36648578)
21. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
22. Niwa H, Masui S, Chambers I, Smith AG and Miyazaki J: Phenotypic complementation establishes requirements for specific POU domain and generic transactivation function of Oct-3/4 in embryonic stem cells. Mol Cell Biol 22: 1526-1536, 2002.
23. Yasuda K, Yashiro M, Sawada T, Ohira M and Hirakawa K: ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells. Anticancer Res 27: 4071-4075, 2007.
24. Miyoshi J, Kagimoto M, Soeda E and Sakaki Y: The human c-Ha-ras2 is a processed pseudogene inactivated by numerous base substitutions. Nucleic Acids Res 12: 1821-1828, 1984.